Obecabtagene autoleucel
- Generic Name
- Obecabtagene autoleucel
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 760HJB0YRD
- Background
Obecabtagene autoleucel is an investigational autologous CD19 CAR T cell therapy.
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin LymphomaRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Autolus Limited
- Target Recruit Count
- 30
- Registration Number
- NCT06173518
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Nino Jesus, Madrid, Spain
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath